Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer

By News Health
2 days Ago

(MedPage Today) — CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in certain patients with locally advanced head and neck squamous cell carcinoma (HNSCC), according…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115840

Author :

Publish date : 2025-06-01 21:35:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Football Training Benefits Patients With Heart Issues

PARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer

GLP-1 Less Frequent Dosing May Maintain Weight Loss

Inexpensive HIV Med Improves Vision in Diabetic Eye Disease

Does Initial Progression of SSc-ILD Mean More Is to Come?

Quarter of people follow rules even with no downside to breaking them